Dachaigh › Aillse Sgamhain Neo-chealla-beag › Virginia › Charlottesville
Sgrùdaidhean clionaigeach Aillse Sgamhain Neo-chealla-beag ann an Charlottesville, VA
Tha 21 sgrùdaidhean airson Aillse Sgamhain Neo-chealla-beag a’ lorg phàirtichean aig làraichean ann agus timcheall air Charlottesville (taobh a-staigh mu 30 mìle). Fosglaidh sgrùdadh gus faicinn cò as urrainn pàirt a ghabhail agus mar a chuireas tu fios air an sgioba.
Teacsa sgrùdaidh oifigeil (Beurla)
A’ fastadh airson sgrùdadh an seo? Seall e aig mullach na duilleige seo — $99 airson 30 latha →
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
A’ fastadhÌre 1
- Exelixis Clinical Site #66, Charlottesville
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
A’ fastadhÌre 2
- University of Virginia, Charlottesville
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A’ fastadhÌre 3
- UVA Comprehensive Cancer Center, Charlottesville
- UVA Health Fontaine Research Park, Charlottesville
- University of Virginia, Charlottesville
- agus 1 a bharrachd
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
A’ fastadhÌre 2
- University of Virginia Cancer Center, Charlottesville
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
A’ fastadhÌre 3
- University of Virginia Health System, Charlottesville
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
A’ fastadhÌre 2/3
- University of Virginia Health System, Charlottesville
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
A’ fastadhÌre 3
- Clinical Study Site, Charlottesville
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
A’ fastadhÌre 3
- University of Virginia Health System, Charlottesville
Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation
A’ fastadhÌre 1/2
- University of Virginia Cancer Center, Charlottesville
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
A’ fastadhÌre 3
- Research Site, Charlottesville
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
A’ fastadhÌre 3
- University of Virginia, Charlottesville
Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node or Other High Risk Features
A’ fastadhÌre 2
- UVA Comprehensive Cancer Center, Charlottesville
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
A’ fastadhÌre 2
- University of Virginia Cancer Center, Charlottesville
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
A’ fastadhÌre 2
- University of Virginia Cancer Center, Charlottesville
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
A’ fastadhÌre 2/3
- University of Virginia Cancer Center, Charlottesville
Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
A’ fastadhÌre 2
- University of Virginia Health System, Charlottesville
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
A’ fastadhÌre 1/2
- University of Virginia, Charlottesville
Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases
A’ fastadhÌre 2
- University of Virginia Health System, Charlottesville
GEMINI-NSCLC: NSCLC Biomarker Study
A’ fastadhSgrùdadh amharc
- University of Virginia, Charlottesville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
A’ fastadhSgrùdadh amharc
- Massive Bio SYNERGY-AI site, Charlottesville
A Study of NX-1607 in Adults With Advanced Malignancies
A’ fastadhÌre 1
- University of Virginia, Charlottesville
Sgrùdaidhean Aillse Sgamhain Neo-chealla-beag ann am bailtean eile
- Houston, TX145 sgrùdaidhean
- New York City, NY121 sgrùdaidhean
- Arlington, VA104 sgrùdaidhean
- Nashville, TN97 sgrùdaidhean
- Boston, MA90 sgrùdaidhean
- Los Angeles, CA87 sgrùdaidhean
- St. Louis, MO73 sgrùdaidhean
- Chicago, IL61 sgrùdaidhean
- Baltimore, MD60 sgrùdaidhean
- San Antonio, TX59 sgrùdaidhean
- Columbus, OH57 sgrùdaidhean
- Washington, DC55 sgrùdaidhean
Sgrùdaidhean eile ann an Charlottesville
- Leukemia myeloid geur16 sgrùdaidhean
- Aillse Prostata15 sgrùdaidhean
- Aillse (gach seòrsa)13 sgrùdaidhean
- Ailse Endometrial13 sgrùdaidhean
- Ailse metastatach13 sgrùdaidhean
- Ailseachadh nan Sgamhan13 sgrùdaidhean
- Fàilligeadh a' Chridhe12 sgrùdaidhean
- Aillse colorectal10 sgrùdaidhean
- Cancer Ovarian10 sgrùdaidhean
- Diabetes Type 19 sgrùdaidhean
- Aillse a' bhroilleach9 sgrùdaidhean
- Cancer Pancreatic9 sgrùdaidhean
Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.